LLY vs INCY
By Alex · Tickerpine
Eli Lilly and Company vs Incyte Corporation, side by side — the numbers that matter, in plain English. No “winner” hype; you decide.
| Metric | LLY | INCY |
|---|---|---|
| Price | $1,233.66 | $129.72 |
| Market cap | $1.10T | $26.29B |
| P/E ratio | 41.8 | 16.5 |
| ROE | 102.29% | 30.67% |
| Profit margin | 33.53% | 27.71% |
| Revenue growth | 47.70% | 37.70% |
| Dividend yield | 0.55% | — |
| Beta | 0.51 | 0.77 |
Green = the more favorable figure for that metric (lower P/E, higher ROE, margin, growth and yield). Not a recommendation.
LLY vs INCY in plain English
- LLY is the bigger company — about 41.8× the market cap of INCY.
- INCY is cheaper on earnings (P/E 16.5 vs 41.8).
- LLY earns a higher return on equity (102% vs 31%).
- LLY is growing revenue faster (48% vs 38%).
- LLY pays a dividend (0.55%) while the other effectively doesn't.
How would $1,000 have done in each?
LLY return calculator
See what $1,000 in Eli Lilly and Company would be worth today.
INCY return calculator
See what $1,000 in Incyte Corporation would be worth today.
Figures from public market data, may be delayed. Comparison is informational only — not investment advice.